To identify patients who can safely evade the magnetic resonance imaging fusion-targeted biopsy (MRIFTB) for prostate imaging reporting and data system (PI-RADS) 3 lesion.
Overall, 755 men with PI-RADS 3-5 lesions who underwent MRIFTB were retrospectively analyzed.